{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=11", "query": { "condition": "Other Lung Disease", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 252, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Lung+Disease&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T20:25:31.788Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07602842", "title": "A Study of IDP-001 in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Head and Neck Squamous Cell Carcinoma", "Cutaneous Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Cervix", "Non Squamous Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Esophagus", "Squamous Cell Carcinoma of the Anus", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "IDP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InduPro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2026-07-08", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 6, "location_summary": "Los Angeles, California • Sarasota, Florida • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07602842" }, { "nct_id": "NCT03518554", "title": "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Head and Neck Cancer", "Esophageal Cancer", "Other Metastatic Solid Tumors" ], "interventions": [ { "name": "JAB-3068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2018-04-23", "completion_date": "2022-02-03", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03518554" }, { "nct_id": "NCT04119024", "title": "Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Uveal Melanoma", "Acral Melanoma", "Neuroendocrine Tumors", "Paraganglioma", "Pheochromocytoma", "Adrenocortical Carcinoma", "Pancreatic Neuroendocrine Tumor", "Thyroid Cancer", "Breast Cancer", "Lung Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Anusha Kalbasi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2025-10-07", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04119024" }, { "nct_id": "NCT01719861", "title": "Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer (SCLC)", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Desipramine HCL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joel Neal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-10", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2017-04-17", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01719861" }, { "nct_id": "NCT04079179", "title": "Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Langerhan's Cell Histiocytosis", "Juvenile Xanthogranuloma", "Erdheim-Chester Disease", "Rosai Dorfman Disease", "Neuro-Degenerative Disease", "Histiocytic Sarcoma", "Histiocytic Disorders, Malignant" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 90, "start_date": "2021-04-19", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04079179" }, { "nct_id": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Solid Tumor", "CRAF Gene Amplification", "RAF1 Gene Amplification", "BRAF Gene Fusion", "BRAF Fusion", "CRAF Gene Fusion", "CRAF Fusion", "RAF1 Gene Fusion", "RAF1 Fusion", "Thyroid Cancer, Papillary", "Spitzoid Melanoma", "Pilocytic Astrocytoma", "Pilocytic Astrocytoma, Adult", "Non Small Cell Lung Cancer", "Non-Small Cell Adenocarcinoma", "Colorectal Cancer", "Pancreatic Acinar Carcinoma", "Spitzoid Malignant Melanoma", "Bladder Cancer", "Bladder Urothelial Carcinoma", "MAP Kinase Family Gene Mutation", "RAF Mutation" ], "interventions": [ { "name": "Tovorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Day One Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 23, "start_date": "2021-07-15", "completion_date": "2024-07-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 8, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04985604" }, { "nct_id": "NCT03688347", "title": "Microbiome in Lung Cancer and Other Malignancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Cancer", "Malignancy" ], "interventions": [ { "name": "Nasal Swab", "type": "PROCEDURE" }, { "name": "Oral Swab", "type": "PROCEDURE" }, { "name": "Stool Collection", "type": "OTHER" }, { "name": "Microbiome analysis", "type": "GENETIC" }, { "name": "DNA Banking", "type": "GENETIC" }, { "name": "Skin Swab", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "GENETIC" ], "sponsor": "Taher Abu Hejleh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 44, "start_date": "2018-08-30", "completion_date": "2022-05-09", "has_results": false, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03688347" }, { "nct_id": "NCT04440943", "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "MSI-H Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-527", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-08-04", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04440943" }, { "nct_id": "NCT07278479", "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Large Cell Neuroendocrine Carcinoma", "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Small Cell Lung Cancer (SCLC)", "Gastroenteropancreatic NEC (GEP NEC)", "NEC of the Bladder", "Other DLL3 Expressing epNEC" ], "interventions": [ { "name": "[212Pb]Pb-MP0712", "type": "DRUG" }, { "name": "[203Pb]Pb-MP0712", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Molecular Partners AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2026-05-18", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 6, "location_summary": "Tampa, Florida • Atlanta, Georgia • Glen Burnie, Maryland + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278479" }, { "nct_id": "NCT04359680", "title": "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "Viral Respiratory Illnesses" ], "interventions": [ { "name": "Nitazoxanide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vitamin Super B-Complex", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Romark Laboratories L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1407, "start_date": "2020-05-13", "completion_date": "2021-04-07", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-13T20:25:31.788Z", "location_count": 26, "location_summary": "Hot Springs, Arkansas • Huntington Beach, California • Long Beach, California + 21 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04359680" } ] }